Review: proposed ferroptosis–inflammaging axis in age-associated degenerative disorders
This review explores a proposed ferroptosis–inflammaging axis linking iron-dependent cell death to inflammation and tissue failure in age-associated degenerative disorders, and discusses natural products as possible ferroptosis modulators. [1]
Automatic summary · not editorially reviewed
The key findings
The review proposes a ferroptosis–inflammaging axis and examines it in neurodegenerative, cardiovascular, metabolic, pulmonary and musculoskeletal disorders. [1]
Ferroptosis is described as an iron-dependent type of controlled cell death possibly linking inflammation, oxidative damage and tissue failure with ageing. [1]
Natural products are highlighted as possible ferroptosis modulators, with growing data from experimental models and unresolved translational difficulties. [1]
The source at a glance
- Study type / format
- Narrative review (abstract only)
- Population / context
- People with age-associated degenerative disorders, grouped as neurodegenerative, cardiovascular, metabolic, pulmonary and musculoskeletal problems (review scope).
- Summary based on
- Study abstract
- Original publication
- October 1, 2026
Proposed axis across five disorder groups
The review connects persistent low-grade inflammation, oxidative stress, cellular senescence and disturbed cellular homeostasis with ageing and age-related disease. It presents ferroptosis, an iron-dependent form of controlled cell death, as a possible key link between inflammation, oxidative damage and tissue failure as people age. The authors call this the ferroptosis–inflammaging axis and examine it in neurodegenerative, cardiovascular, metabolic, pulmonary and musculoskeletal problems. This is a proposed framework, not an established mechanism.
Supporting source [1]
Natural products as possible modulators
The review gives particular attention to natural products as possible ferroptosis modulators. It stresses their therapeutic significance and the growing data from experimental models. These findings come from experimental models, not from demonstrated benefits for human lifespan or healthy ageing. The abstract does not name specific compounds, doses or model organisms.
Supporting source [1]
Translational hurdles named by the review
The review also lists translational difficulties for ferroptosis-targeted therapies: lack of clinical validation, development of biomarkers, pharmacokinetic issues and disease-specific treatment approaches. It concludes that understanding the axis may offer a foundation for finding new strategies to delay tissue dysfunction and enhance healthy ageing. This is a research outlook, not a promise of benefit.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is a review of a proposed framework, and the abstract reports no clinical validation, specific compounds, doses or human outcome data.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Mandlik DS, Mandlik SK. · europepmc.org · October 1, 2026